ImmunityBio(IBRX)
SAN DIEGO, CA
Biotechnology2 H-1B visas (FY2023)Focus: Cellular therapy
ImmunityBio is a life sciences company focused on Cellular therapy.
OncologyCell Therapy
Funding Stage
PUBLIC
Open Jobs
68
Pipeline & Clinical Trials
rMBCG
NMIBCClinical Trials (1)
NCT06810141ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
N/AN803 plus Bacillus Calmette-Guerin
Non Muscle Invasive Bladder CancerClinical Trials (1)
NCT05981131Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
N/Anogapendekin-alfa inbakicept
LymphopeniaClinical Trials (1)
NCT06956547Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy
N/AhAd5-S-Fusion+N-ETSD vaccine
COVID-19Clinical Trials (1)
NCT04591717COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers
Phase 1N-803
COVID-19Clinical Trials (1)
NCT04385849Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19
Phase 1aldoxorubicin
Advanced Solid TumorClinical Trials (1)
NCT01673438Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors
Phase 1aldoxorubicin
Metastatic Solid TumorsClinical Trials (1)
NCT02235688Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
Phase 1Phase 1
Clinical Trials (1)
NCT05618925Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
Phase 1N-803
HIV InfectionClinical Trials (1)
NCT04340596Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
Phase 1N-803
Healthy SubjectsClinical Trials (1)
NCT06040918Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis
Phase 1CD19 t-haNK
Diffuse Large B Cell LymphomaClinical Trials (1)
NCT04052061QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
Phase 1haNK™ for Infusion
Solid TumorClinical Trials (1)
NCT03027128QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors
Phase 1CD19 t-haNK
Non-Hodgkin Lymphoma Refractory/ RelapsedClinical Trials (1)
NCT06334991Study for Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma
Phase 1aldoxorubicin
Advanced Solid TumorsClinical Trials (1)
NCT01706835Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
Phase 1Neukoplast™
Acute Myeloid LeukemiaClinical Trials (1)
NCT00900809QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia
Phase 1IBRX-042
HPV-Related CarcinomaClinical Trials (1)
NCT05976828IBRX-042 In Participants With HPV-Associated Tumors
Phase 1Nogapendekin Alfa Inbakicept
Metastatic Urothelial CarcinomaClinical Trials (1)
NCT07217496N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
Phase 1Phase 1
Clinical Trials (1)
NCT07049432N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Phase 1M-CENK, Suspension for Infusion, Cryopreserved
Metastatic Solid TumorClinical Trials (1)
NCT04898543QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 1PD-L1 t-haNK
Locally Advanced Solid TumorClinical Trials (1)
NCT04050709QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
Phase 1BM-Allo.MSC
COVIDClinical Trials (1)
NCT04397796Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation
Phase 1INNO-206
Malignant Solid TumourClinical Trials (1)
NCT01337505Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors
Phase 1hAd5-S-Fusion+N-ETSD
Covid19Clinical Trials (1)
NCT04732468COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA
Phase 1hAd5-S-Fusion+N-ETSD vaccine
Covid19Clinical Trials (1)
NCT04710303COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults
Phase 1avelumab
Non Hodgkin LymphomaClinical Trials (1)
NCT03169790QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
Phase 1/2Aldoxorubicin HCl
Pancreatic CancerClinical Trials (1)
NCT03586869QUILT-3.080: NANT Pancreatic Cancer Vaccine
Phase 1/2Avelumab
Ovarian CancerClinical Trials (1)
NCT03197584QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
Phase 1/2avelumab
Non-small Cell Lung CancerClinical Trials (1)
NCT03169738QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
Phase 1/2avelumab
Urothelial CarcinomaClinical Trials (1)
NCT03197571QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1/2avelumab
Triple Negative Breast CancerClinical Trials (1)
NCT03175666QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
Phase 1/2avelumab
Colorectal CancerClinical Trials (1)
NCT03169777QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
Phase 1/2Aldoxorubicin HCl
Triple Negative Breast CancerClinical Trials (1)
NCT03387085QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
Phase 1/2170 mg/m2 aldoxorubicin
Metastatic, Locally Advanced, or Unresectable Soft Tissue SarcomaClinical Trials (1)
NCT02235701Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma
Phase 1/2AAHI-SC2 Vaccine
COVID-19Clinical Trials (1)
NCT05370040THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines
Phase 1/2Avelumab
Merkel Cell CarcinomaClinical Trials (1)
NCT03167164QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
Phase 1/2Fludarabine
Leukemia, Myeloid, AcutePhase 1/2
Clinical Trials (1)
NCT03563170QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT05304936HCW9218 for Advanced Pancreatic Cancer
Phase 1/2ALT-803
Pancreatic CancerClinical Trials (1)
NCT03329248QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Phase 1/2Intravesical Recombinant Mycobacterium
NMIBCClinical Trials (1)
NCT06800963ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
Phase 1/2Aldoxorubicin Hydrochloride
Colorectal Cancer MetastaticClinical Trials (1)
NCT03563157QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
Phase 1/2hAd5-S-Fusion+N-ETSD vaccine
Covid19Clinical Trials (1)
NCT04843722COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT04927884A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
Phase 1/2BCG+N-803
Non-muscle Invasive Bladder CancerClinical Trials (1)
NCT02138734A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Phase 1/2Avelumab
MelanomaClinical Trials (1)
NCT03167177QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1/2Aldoxorubicin Hydrochloride
ChordomaClinical Trials (1)
NCT03647423QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
Phase 1/2Aldoxorubicin HCl
Pancreatic CancerClinical Trials (1)
NCT03387098QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Phase 1/2Cyclophosphamide
Pancreatic CancerClinical Trials (1)
NCT03136406QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Phase 1/2Aldoxorubicin HCl
Squamous Cell CarcinomaClinical Trials (1)
NCT03387111QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT03169764QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1/2Open Jobs (68)
Principal Scientist, Regulatory CMC
Summit, NJ
Yesterday
Agency Temporary-Senior CRA, Field Monitor
Yesterday
Digital Media Specialist, Patient Recruitment
San Francisco, CA
Yesterday
Specialist III, Regulatory Lifecycle Maintenance
Summit, NJ
Yesterday
Agency Temporary – CRA II, Field Monitor
Yesterday
Senior Scientist, Regulatory CMC
Summit, NJ
Yesterday
Associate Director, Regulatory CMC
Summit, NJ
Yesterday
Area Business Director – South Central
4d ago
Area Business Director - North Central
4d ago
QA Specialist, Quality Operations
Culver City CA 9522
4d ago
Program Manager – Engineering Projects
El Segundo CA Mariposa
4d ago
Senior Specialist, Analytical & Microbiology QA
Culver City CA 9522
4d ago
Clinical Research Associate I, Field Monitor
4d ago
Clinical Implementation Director
5d ago
Veeva RIM Specialist
Summit, NJ
6d ago
Clinical Research Associate, In-House
6d ago
Manager, Veeva RIM
Summit, NJ
6d ago
Regulatory Documentation Specialist II
Summit, NJ
6d ago
Clinical Trials Associate
6d ago
Regulatory Documentation Specialist III
Summit, NJ
6d ago
Senior Specialist, Manufacturing GMP Investigations
El Segundo, CA
1w ago
Temporary - Clinical Trials Manager
1w ago
Senior Clinical Trials Manager
1w ago
IB Temporary - Outsourcing & Budget Management
Torrey Pines, CA
1w ago
Clinical Research Associate II, Field Monitor
1w ago
Interview Prep Quick Facts
Portfolio: 75 clinical trials
Top TAs: Oncology, Infectious Diseases
H-1B (2023): 2 approvals
SEC Filings: 2 available
Open Roles: 68 active jobs
Hiring Trend
Actively Hiring
68
Open Roles
+33
Added
-5
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub